In a trial of 36 patients with T2D, canagliflozin caused an increase in total urine volume without any significant change in plasma volume at 12 weeks.15 In another small observational study in patients with CKD, dapagliflozin was associated with preferential reduction in extracellular water in comparison to furosemide.16 As a potential HF therapy, SGLT2 inhibitors could be frequently prescribed alongside loop diuretics, but there are little data on coadministration. This evidence concerns the gene SLC5A2 and chronic kidney disease.